Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
THE AMERICAL JOURNAL OF PSYCHIATRY
Fecha de publicación: Marzo 2018
DOI: https://doi.org/10.1176/appi.ajp.2017.17030325
Autores: Philip McGuire, F.R.C.Psych., F.Med.Sci., Philip Robson, M.R.C.P., F.R.C.Psych., Wieslaw Jerzy Cubala, M.D., Ph.D., Daniel Vasile, M.D., Ph.D., Paul Dugald Morrison, Ph.D., M.R.C.Psych., Rachel Barron, B.Vet.Med., M.R.C.V.S., Adam Taylor, Ph.D., Stephen Wright, F.R.C.P.(Edin), F.F.P.M.
Background: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.
